Molecules, Microbes And Multiomics

Sinopse

Molecules, microbes and multiomics is DNA Genotek's podcast, featuring experts in all areas of the genomics, microbiome and multiomics space. To learn more about any of these emerging areas of science, tune in.

Episódios

  • Metabolomics and the microbiome

    Metabolomics and the microbiome

    28/08/2020 Duração: 22min

    The question of “What is Metabolomics” has been buzzing around the scientific community. With the advances of new technology, a gateway to studying metabolomics has been opened. Over recent years, microbiome researchers have begun to incorporate  metabolomics, the “missing piece of the puzzle”, as part of their multiomics studies  To understand that missing piece more clearly and what it could mean for the future of multiomics, we feature two experts from DNA Genotek,  Dr. Heloise Breton, Product Manager for Microbiome products, and Dr. Olle de Bruin, R&D Scientist - microbiome/metabolomics.

  • Solving the mysteries of your pet’s gut health

    Solving the mysteries of your pet’s gut health

    13/08/2020 Duração: 29min

    Nom Nom is not your average pet food company.  In addition to delivering fresh, healthy meals for cats and dogs created by a team of veterinary nutritionists, they use gut microbiome samples submitted by their customers to study the link between nutrition and pet health.  Nom Nom partners with Diversigen to analyze these samples and provide the accurate sequencing and bioinformatics analysis the Nom Nom scientists require to learn about the impact of nutrition on pet health. We speak with Dr. Ryan Honaker, the director of Microbiology at Nom Nom, in the latest episode of our Molecules, Microbes, and Multiomics Podcast.

  • Detection and full genotyping of Human Papillomavirus (HPV) in first-void urine

    Detection and full genotyping of Human Papillomavirus (HPV) in first-void urine

    17/06/2020 Duração: 24min

    We recently had the opportunity to interview Rebecca Millecamps, a Marketing Manager at Fujirebio, a global leader in the field of in vitro diagnostics (IVD). In 2019, Novosanis and Fujirebio, signed a worldwide, non-exclusive agreement for the distribution of  Colli-Pee®, Novosanis’ urine collection device for use with Fujirebio’s INNO-LiPA HPV genotyping Extra II assay. This partnership enables detection and full genotyping of Human Papillomavirus (HPV) in first-void urine (first 20 mL of urine) collected with Colli-Pee®. In this podcast, Rebecca discusses how urine testing will impact HPV testing, what the benefits are of performing HPV genotyping in urine samples and the future for urine testing for HPV compared to cervical samples. 

  • How to ensure the best sequencing results from saliva and fecal samples

    How to ensure the best sequencing results from saliva and fecal samples

    27/03/2020 Duração: 23min

    DNA Genotek has expertise with many different non-invasive sample types including saliva for genomic and feces for microbiome analysis. With any sample type, quality is paramount to generate the best sequencing results and subsequently to produce the most accurate data. In this podcast, Mike Tayeb and Brice LeFrancois, two experts from our research and development team highlight the best practices they use in the lab with saliva and fecal samples to get optimal sequencing results.

  • SPARK project provides evidence for autism risk genes

    SPARK project provides evidence for autism risk genes

    25/02/2020 Duração: 13min

    This episode of Molecules, microbes and multiomics features an interview with Pamela Feliciano, Ph.D. who is the Scientific Director for SPARK (Simons Foundation Powering Autism Research through Knowledge)  Launched in 2016, SPARK is designed to speed up research and advance our understanding of autism. SPARK, the largest study of autism ever, aims to make important progress possible. Learn about their project and why they use DNA saliva collection as their method of choice. 

  • Industry leaders come together to support microbiome discovery

    Industry leaders come together to support microbiome discovery

    13/02/2020 Duração: 28min

    As the microbiome industry grows and evolves, so has our team of microbiome experts. In 2019, DNA Genotek’s parent company, OraSure, acquired both CoreBiome and Diversigen. Through these acquisitions, we gained Diversigen's industry recognized CLIA/CAP state-of-the-art techniques with expert consultative microbiome services, and the strength of CoreBiome's innovative scalable sequencing technology.  In this podcast, Lisa Gamwell, Services Product Manager at DNA Genotek speaks with Dan Knights, CEO of CoreBiome and Joy Nassif, Chief Operating Officer at Diversigen, to discuss their companies and how these teams will to work together to help advance the microbiome industry as a whole. 

  • Multiomics methods investigating aging process in mans best friend

    Multiomics methods investigating aging process in man's best friend

    11/12/2019 Duração: 39min

    DNA Genotek speaks with researchers involved in the recently launched Dog Aging Project. The goal of the Dog Aging Project is to understand how genes, lifestyle, and environment influence aging and to use that information to help pets and people increase healthspan, the period of life spent free from disease. In this podcast, we speak with Dr. Daniel Promislow from the Dog Aging Project, Dr. Elinor Karlsson from the Darwin's Ark Project and Dr. Janet Patterson-Kane from the Golden Retriever's Lifetime study. 

  • The role of the microbiome in childhood determinants of cardiovascular health

    The role of the microbiome in childhood determinants of cardiovascular health

    05/11/2019 Duração: 22min

    The Cardiovascular Risk in Young Finns Study is a prospective longitudinal study initiated in 1980. It is one of the largest follow-up studies into cardiovascular risk from childhood to adulthood. The main aim is to determine the contribution made by childhood lifestyle, biological, and psychological measures to the risk of cardiovascular diseases in adulthood. In this podcast, Dr. Katja Pahkala and Dr. Evelina Munukka from the Univeristy of Turku, Finland apeak about this study, why they recently incorporated gut microbiome samples as part of their research, and what role the gut microbiome could play in cardiovascular health.

  • PREdiCCT: the largest study on predicting IBD disease flare

    PREdiCCT: the largest study on predicting IBD disease flare

    17/09/2019 Duração: 27min

    This week, I interview Dr. Charlie Lees and Lee Murphy, investigators for the PREdiCCt Study (Prognostic effect of environmental factors in Crohn’s and Colitis). PREdiCCt is a major study at the University of Edinburgh that is actively recruiting now. This is the first study of its kind and it is directed towards understanding how environmental factors and the gut microorganisms influence Inflammatory Bowel Disease (IBD) flare and recovery. In this podcast, I speak with Chief Investigator Dr. Charlie Lees and Lee Murphy, Genetics Manager at the Edinburgh Clinical Research Facility about the progress to date on the PREdiCCt study, and what they hope to learn.

  • The challenges and opportunities of collecting RNA for human microbiome studies

    The challenges and opportunities of collecting RNA for human microbiome studies

    09/09/2019 Duração: 16min

    Jean Macklaim is a Bioinformatician at DNA Genotek who has an extensive history with RNA research. Jean received her PhD in Biochemistry and Bachelor of Science in Human Genetics from the University of Western Ontario where she focused on sequencing technologies and bioinformatics methods to understand the structure and function of the microbiome in different disease and environmental conditions. In this podcast, Jean speaks about the challenges and potential RNA has in both the research and clinical fields for human microbiome.

  • The Art of Innovation

    The Art of Innovation

    16/07/2019 Duração: 07min

    An interview with Stephen Tang, President and CEO of OraSure Technologies and its subsidiaries DNA Genotek, CoreBiome and Novosanis. Steve spoke about how he fosters a culture of innovation across the entire organization. In the podcast, he discusses how innovation helps the organization respond to change, how developing people and creating opportunities for them makes them more innovative and how he ensures innovation is not a one time project.

  • Saliva as a sample type for genomic applications

    Saliva as a sample type for genomic applications

    07/06/2019 Duração: 14min

    This week, I interview Scott Rabuka, Director of the Genomics Program at DNA Genotek for our podcast, Molecules, Microbes and Multiomics. Scott joined DNA Genotek in 2008 as the product manager for Oragene and successfully expanded the product into a complete family of solutions for global genomic research and clinical use. He is responsible for the launch of the company's first FDA 510(k) cleared product in 2011 as well as multiple new products designed to address evolving global market opportunities. In this podcast, Scott speaks about saliva as a DNA sample type, who’s using it today and how it compares to other sample types in the field, the clinic and in the lab.

  • Urine as a liquid biopsy for cancer detection

    Urine as a liquid biopsy for cancer detection

    23/04/2019 Duração: 10min

    We recently had the opportunity to visit our new sister company, Novosanis, in Antwerp, Belgium, to talk about urine as a sample type. Novosanis is dedicated to solving urine sampling challenges through its product Colli-Pee™ - an award-winning device designed to efficiently and hygienically capture first-void urine (the first 20ml of a urine sample). I spoke with their CEO and co-founder, Vanessa Vankerckhoven about the challenges first void urine collection solves for both cancer detection as well as STIs. 

  • A look ahead for the microbiome industry

    A look ahead for the microbiome industry

    27/03/2019 Duração: 16min

    We recently introduced listeners of Molecules, microbes and multiomics to our sister company, CoreBiome, a privately-held, Minnesota-based microbiome analysis company that accelerates discovery for customers in the pharmaceutical, agricultural, environmental and research communities. We are continuing this story via an interview with CoreBiome co-founder, Dr. Dan Knights. In this new podcast, Dr. Knights speaks to us about why the microbiome is so different from the human genome, what answers microbiome research can provide for wellness and disease that we can’t find elsewhere, and what advice he would give an epidemiologist who is looking to add a microbiome component to their project.

  • The microbiome challenges CoreBiome was built to solve

    The microbiome challenges CoreBiome was built to solve

    04/03/2019 Duração: 08min

    In the podcast, Dr. Dan Knights, co-founder and CEO of CoreBiome discusses the problems CoreBiome was built to solve and the challenges surrounding reproducibility in the microbiome field. You’ll learn why he “geeks out” about quality, efficiency, and accuracy and how his team keeps CoreBiome at the forefront of the microbiome industry. Learn more about CoreBiome and what it can do for microbiome researchers and clinicians here.

Informações: